Investor Relations


Investor Relations

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells.


Corporate Presentation

The following is an investor update, effective January 2023, presented by Robert Bitterman. Mr. Bitterman was recently appointed Executive Chairman and Principal Executive Officer.

Download Phio Corporate Presentation

Market Value
As of
Provided by Refinitiv.